Skip to main content
SpringerLink
Log in

BRAF testing not cost effective in advanced melanoma

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. mitogen-activated protein kinase

  2. 2019 US dollars

  3. willingness-to-pay

Reference

  • Wu B, et al. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. JAMA Dermatology : 22 Jul 2020. Available from: URL: http://doi.org/10.1001/jamadermatol.2020.2398

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

BRAF testing not cost effective in advanced melanoma. PharmacoEcon Outcomes News 859, 5 (2020). https://doi.org/10.1007/s40274-020-7014-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-7014-z

Search

Navigation